Nervgen Pharma Corp Stock Price, News & Analysis

NervGen Pharma (OTCQB: NGENF) announced a significant leadership change as President and CEO Mike Kelly steps down, with Board Chairman Dr. Adam Rogers appointed as Interim CEO. The transition follows the company's successful completion of landmark positive results from the chronic cohort of the CONNECT SCI study for their lead candidate NVG-291.

Under Kelly's leadership, NervGen achieved the strongest efficacy signal observed to date in spinal cord injury treatment through their CONNECT SCI study. The company is now preparing to advance discussions with regulators and the SCI community regarding NVG-291's development, which represents a potential best-in-class therapy for spinal cord injury and other nervous system disorders.

NervGen Pharma (OTCQB: NGENF), a clinical-stage biotech company focused on neurological treatments, has provided updates on its ATM Program and stock options. Under the ATM Program, the company sold 385,200 common shares at $2.95 per share during Q2 2025, generating gross proceeds of $1.13 million and net proceeds of $1.11 million after fees.

Additionally, NervGen granted 200,000 stock options to a director, exercisable at $3.55 per share for five years, with quarterly vesting over one year.

NervGen Pharma (OTCQB: NGENF), a clinical-stage biotech company focused on neurological treatments, announced key leadership changes to its Board of Directors. Dr. Adam Rogers, representing the company's largest shareholder, has been unanimously appointed as the new Board Chair, succeeding Glenn Ives who resigned after four years of service.

The leadership transition comes at a strategic time following positive topline results from the chronic cohort of the Phase 1b/2a CONNECT SCI Study for NVG-291, the company's neuroreparative therapy candidate. Dr. Rogers, who previously served as NervGen's interim president, brings significant expertise as a board-certified physician and biotech entrepreneur, having co-founded Hemera Biosciences and developed HMR59, now in clinical trials as JNJ-1887.

NervGen Pharma (OTCQB: NGENF), a clinical-stage biotech company, announced the resignation of Chief Medical Officer Daniel Mikol, MD, Ph.D. Dr. Randall Kaye, recently appointed Chief Medical Advisor, will expand his role while the company searches for a new CMO.

The transition comes as NervGen advances its lead candidate NVG-291 following positive topline results in a Phase 1b/2a clinical trial for chronic cervical spinal cord injury. Dr. Mikol completed the chronic cohort study before his departure, and the company is now preparing for regulatory engagement as it moves toward late-stage development.

[ "Positive topline results achieved in Phase 1b/2a trial for NVG-291 in chronic cervical spinal cord injury", "Seamless leadership transition with Dr. Randall Kaye expanding his role as Chief Medical Advisor", "Successfully completed chronic cohort study before CMO transition" ]

NervGen Pharma has appointed Dr. Randall Kaye as Chief Medical Advisor, expanding his role beyond his current positions as Board Member and Science Committee Chair since 2020. This appointment follows positive topline results in the chronic cohort of NVG-291's Phase 1b/2a trial for cervical spinal cord injury. Dr. Kaye brings extensive experience in CNS therapeutic development, regulatory strategy, and medical affairs. His most recent role was as Chief Medical Officer at Longboard Pharmaceuticals, where he contributed to CNS development programs leading to a $2.6 billion acquisition by H. Lundbeck A/S. Dr. Kaye will assist in analyzing chronic cohort data and help prepare for an upcoming FDA meeting in late 2025.

NervGen Pharma reported positive topline results from the chronic cohort of its Phase 1b/2a trial evaluating NVG-291 in spinal cord injury patients. The study achieved statistical significance in one of two co-primary endpoints, showing a threefold increase in hand muscle motor connectivity compared to placebo. The trial demonstrated improved electrical connectivity between brain and hand muscle in cervical SCI patients, with a p-value of 0.0155. Secondary endpoints showed positive trends in GRASSP scores, particularly in quantitative prehension, with 50% of NVG-291 patients showing at least 4-point improvement versus 10% in placebo. NVG-291 was generally safe and well-tolerated, with only mild/moderate injection site reactions reported. As the first pharmaceutical candidate to demonstrate improved motor recovery through increased motor evoked potential amplitude, this represents a significant advancement in SCI treatment where no approved pharmaceuticals currently exist for sustained functional recovery.

NervGen Pharma (OTCQB: NGENF) announced it will present topline results from the chronic cohort of its Phase 1b/2a study of NVG-291 at the 52nd American Spinal Injury Association Annual Scientific Meeting in June 2025. The presentation will cover data from their initial proof-of-concept, double-blind, placebo-controlled clinical trial in spinal cord injury (SCI). The study incorporated both clinical and electrophysiological assessments to maximize the probability of observing efficacy signals. Dr. Daniel Mikol, NervGen's Chief Medical Officer, will present the findings on June 3, 2025, during the Clinical Trial Updates session in Scottsdale, Arizona.

NervGen Pharma (OTCQB: NGENF), a clinical-stage biotech company focused on neuroreparative therapeutics, has announced the granting of 600,000 incentive stock options. The options are structured as follows:

- 500,000 options granted to Directors, exercisable at $4.00 per share for 5 years, vesting quarterly over 1 year
- 100,000 options granted to employees, exercisable at $4.00 per share for 10 years, vesting semi-annually over 4 years

All options comply with TSX Venture Exchange policies and the company's stock option plan.

NervGen Pharma (NGENF) reported its Q1 2025 financial results and operational updates. The company completed the last subject visit in the chronic cohort of its Phase 1b/2a clinical trial for NVG-291 in spinal cord injury (SCI), with topline data expected in early June 2025. The subacute cohort continues enrollment. Key financial metrics: Cash position of $14.5M (down from $17.3M in Q4 2024), Q1 net loss of $3.9M ($0.06 per share), R&D expenses of $3.1M, and G&A expenses of $2.9M. Notable developments include FDA approval for an expanded access protocol for NVG-291, promising preclinical results for NVG-300 in stroke and SCI models, and protocol amendments to facilitate enrollment in the subacute cohort. The company raised approximately $1.3M through ATM and warrant exercises during Q1, with an additional $2.5M raised post-quarter.